Nexalin Technology and UCSD Collaborate on Innovative Clinical Trial
Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW) has exciting news to share as they embark on a groundbreaking clinical trial in collaboration with the University of California, San Diego. This trial, led by Dr. Ming Xiong Huang, aims to provide veterans with advanced treatment options for mild Traumatic Brain Injury (mTBI) using their newly designed Gen-3 Halo headset.
A Pioneering Approach to At-Home Care
The Gen-3 Halo headset promises to revolutionize the way treatment is delivered, allowing veterans to receive care from the comfort and privacy of their own homes. This modern approach helps eliminate the barriers often associated with traditional psychiatric visits, particularly the discomfort and stigma that can come with such appointments. The virtual clinic model not only improves accessibility but also offers a more tailored support system for those suffering from mTBI.
Deep Intracranial Frequency Stimulation Technology
At the heart of Nexalin’s innovative offering is their proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, which utilizes an advanced 15 milliamp waveform. Following the promising results of previous clinical trials, this new generation headset seeks to build on that success, looking to enhance the recovery process significantly for veterans experiencing traumatic brain injuries.
Insights and Objectives of the Study
The ongoing study, titled “MEG Study of the Transcranial Electrical Stimulation Treatment for Mild Traumatic Brain Injury using the Nexalin Halo Headset that Utilizes the Advanced 15 Milliamp Waveform,” is designed to explore not only the effects of the headset on brain activity but also the relief of various symptoms related to mTBI. With this study, Nexalin aims to correlate changes in brain signal activity with improvements in post-concussion symptoms and overall neuropsychological performance.
Structured Recruitment for Robust Results
For this research, two participant groups will be established, lending credibility and rigor to the findings. Group 1 will consist of between 20 to 40 individuals receiving real treatment with the Gen-3 Halo headset, while Group 2 will comprise 10 to 20 individuals using a sham device for comparative analysis. This well-defined structure is critical for accurately assessing the effectiveness of the treatment.
Enhancing Telehealth Access for Veterans
The timing of this study aligns perfectly with the Veterans Administration’s goals to expand therapeutic telehealth services, particularly for those dealing with mTBI. With over $17 billion allocated toward mental health services in the VA's Professional Judgement Budget, Nexalin’s initiative is timely and of significant interest. This funding underscores the need for innovative solutions in mental healthcare for veterans.
Continuing the Momentum with Nexalin
Nexalin's commitment to improving mental health through innovative technologies is commendable. Their Gen-3 Halo headset not only reflects technological advancements but also embodies a compassionate approach to mental health care. By building on previous successful trials with their Gen-2 console device, Nexalin shows a promising trajectory in neurological treatment options for veterans.
A Vision for the Future
Mark White, CEO of Nexalin Technology, expressed his enthusiasm regarding this partnership, emphasizing the importance of bringing a more accessible treatment option to veterans. His comments highlight the broader implications of their work, not just in individual recovery but also in the field of neuromodulation and mental health treatments as a whole.
About Nexalin Technology, Inc.
Nexalin Technology, Inc. is dedicated to designing and developing innovative neurostimulation products aimed at combating the pressing mental health challenges faced globally. Their products are designed to be non-invasive and are tailored to provide effective relief for individuals suffering from various mental health issues. With an emphasis on utilizing bioelectronic medical technology, Nexalin hopes to make significant strides in treating these conditions.
Frequently Asked Questions
What is the purpose of the clinical trial announced by Nexalin?
The clinical trial aims to evaluate the effectiveness of Nexalin's Gen-3 Halo headset in treating veterans with mild Traumatic Brain Injury through a virtual clinic model.
How does the Gen-3 Halo headset work?
The Gen-3 Halo headset utilizes advanced Deep Intracranial Frequency Stimulation (DIFS) technology to provide treatment aimed at enhancing brain activity and reducing symptoms associated with mTBI.
What types of participants are being recruited for this study?
The study will recruit two groups of participants: one receiving treatment with the Gen-3 Halo headset and another using a sham device for comparison.
What support is Nexalin Technology receiving from the Veterans Administration?
The study aligns with the Veterans Administration's initiative to expand telehealth services, with significant funding allocated for veterans' mental health care.
What previous studies support Nexalin's current trial?
Previous trials using the Gen-2 console device showed notable improvements in brain activity and pain reduction, which laid the foundation for further exploration with the Gen-3 Halo headset.
